NCT03887130View on ClinicalTrials.gov

Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

March 27, 2007

Primary Completion Date

April 18, 2013

Study Completion Date

April 18, 2013

Conditions
Breast Cancer
Interventions
DRUG

oral vinorelbine

Oral vinorelbine 60 mg/m² on day 1 \& day 8, for cycle 1, and then 80 mg/m² on day 1 \& day 8, every 3 weeks for subsequent cycles

DRUG

Capecitabine

Capecitabine 1000 mg/m² twice a day (2000 mg/m² daily) from day 1 to day 14

DRUG

Gemcitabine 1250 mg/m²

Gemcitabine 1250 mg/m² on day 1 \& day 8

DRUG

Gemcitabine 1000 mg/m²

Gemcitabine: 1000 mg/m² on day 1 \& 8

DRUG

Paclitaxel

Paclitaxel 175 mg/m² on day 1

DRUG

Docetaxel

Docetaxel 75 mg/m² on day 1

All Listed Sponsors
lead

Pierre Fabre Medicament

INDUSTRY

NCT03887130 - Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter